SCOPUS 정보 검색 플랫폼

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 6, 2001, Pages 595-598

Technology evaluation: MetXia-P450, Oxford BioMedica

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOTOXIC AGENT; FLUCYTOSINE; GANCICLOVIR; METXIA P450; PRODRUG; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ARTICLE; BIOTECHNOLOGY; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; GENE CONSTRUCT; GENE THERAPY; GENE TRANSFER; HUMAN; LONG TERMINAL REPEAT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT;

ARYL HYDROCARBON HYDROXYLASES; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; GENE THERAPY; HUMANS; NEOPLASMS; OXIDOREDUCTASES, N-DEMETHYLATING;

UNIDENTIFIED RETROVIRUS;

EID: 0035672798 PISSN: 14648431 EISSN: None Source Type: Journal
DOI: None Document Type: Article

Times cited : (10)

References (19)

1
- 2042489013
- Oxford BioMedica plc. Drug Development pipeline: Gene therapy (cancer), Oxford BioMedica, gene therapy (Parkinson's disease), Oxford BioMedica, gene therapy (HIV), Oxford BioMedica, gene delivery technology, Oxford retroviral vectors, Oxford BioMedica. Company Communication 13 March
- (1997)

2
- 2042484028
- The Oxford Seminar on Gene Therapy
- IDdb Meeting Report 02 May
- (1996)
- Ford, M.¹

3
- 2042428098
- Annual Report 1997 - Oxford Biomedica
- Oxford BioMedica plc Annual Report 31 December
- (1997)

4
- 2042421703
- Oxford BioMedica to provide RPR Gencell with hypoxia technology
- (1998) FDC Reports Pink Sheet , vol.60 , Issue.51 , pp. 20

5
- 2042493981
- Oxford BioMedica releases pre-clinical data on MetXia-P450, the company's first product to go into clinical trial
- Oxford BioMedica plc Press Release 10 June
- (1999)

6
- 2042418377
- Gene Therapy Advisory Committee gives go ahead for Oxford BioMedica breast cancer trial
- Oxford BioMedica plc Press Release 16 December
- (1998)

7
- 2042456066
- Preclinical evaluation of human cytochrome P450 2B6 (CYP2B6) as a therapeutic gene delivered by a retroviral vehicle for gene-directed enzyme prodrug therapy (GDEPT) of cancer
- Abs 4264
- (2000) Proc Am Assoc Cancer Res , vol.41
- Naylor, M.S.¹ Kan, O.² Griffiths, L.³ Sharifah, I.⁴ Badan, D.⁵ Uden, M.⁶ Spearman, H.⁷ Slade, A.⁸ Kingsman, S.M.⁹ Kingsman, A.¹⁰

8
- 2042456065
- Interim results for the 6 months ended 30 June 2000
- Oxford BioMedica plc Press Release 16 August
- (2000)

9
- 2042420898
- Valentis announces collaboration to PEGylate Oxford BioMedica's cancer therapeutic, MetXia
- Valentis Inc Press Release 13 December
- (2000)

10
- 0033962412
- Split-Intron retroviral vectors: Enhanced expression with improved safety
- (2000) J Virol , vol.75 , pp. 2365-2371
- Ismail, S.I.¹ Rohll, J.B.² Kingsman, S.M.³ Kingsman, A.J.⁴ Uden, M.⁵

11
- 2042464389
- The macrophage-exploiting hypoxia with cell-based delivery of GDEPT
- (2000) Am Assoc Cancer Res , vol.41 , pp. 735
- Griffiths, L.¹ Binley, K.² Iqbail, S.³ Kan, O.⁴ Maxwell, P.⁵ Lewis, C.⁶ Harris, A.L.⁷ Kingsman, S.M.⁸ Naylor, S.⁹

12
- 0033198913
- Characterization of physiologically regulated vectors for the treatment of ischemic disease
- (1999) Hum Gene Ther , vol.10 , Issue.13 , pp. 2197-2208
- Boast, K.¹ Binley, K.² Iqball, S.³ Price, T.⁴ Spearman, H.⁵ Kingsman, H.⁶ Kingsman, A.⁷ Naylor, S.⁸

13
- 0032866070
- An adenoviral vector regulated by hypoxia for the treatment of ischemic disease and cancer
- (1999) Gene Ther , vol.6 , Issue.10 , pp. 1721-1727
- Binley, K.¹ Iqball, S.² Kingsman, A.³ Kingsman, S.⁴ Naylor, S.⁵

14
- 0032760019
- Application of protoMASC (TM), a biologically optimized protein PEGylation technology, in cancer vaccination
- (1999) Control Release Soc , vol.26 , pp. 661-662
- Wright, L.C.¹ Gardiner, A.² Malik, F.³ Galea-Lauri, J.⁴ Delagdo, C.⁵ Neale, D.⁶ Fisher, D.⁷ Buckley, R.G.⁸ Kippen, A.D.⁹ Farzaneh, F.¹⁰ Francis, G.E.¹¹

15
- 4244060978
- Development of retroviral transduced hematopoetic stem cells toward a novel approach to cancer gene therapy
- (1999) Biochem Soc Trans , vol.27 , Issue.5
- Freeth, J.S.¹ Iqball, S.² Rohll, J.³ Watt, S.⁴ Lewis, C.E.⁵ Kingsman, S.M.⁶ Naylor, S.⁷

16
- 2042521134
- Oxford Biomedica interim results for the six months ended 30 June 2001
- Oxford BioMedica plc Press Release 01 August
- (2001)

17
- 2042518668
- GTAC approval for development of MetXia clinical programme
- Oxford BioMedica plc Press Release 10 July
- (2001)

18
- 0034909829
- Directed retroviral delivery of human cytochrome P4502B6 for gene-directed prodrug therapy of cancer
- (2001) Cancer Gene Therapy , vol.8 , Issue.7 , pp. 473-482
- Kan, O.¹ Griffiths, L.² Baban, D.³ Iqball, S.⁴ Uden, M.⁵ Spearman, H.⁶ Sung Price, T.⁷ Esapa, M.⁸ Kingsman, S.⁹ Kingsman, A.¹⁰ Slade, A.¹¹ Naylor, A.¹²

19
- 2042488206
- Oxford BioMedica announces first clinical trial results for its cancer theapeutic, MetXia
- Oxford BioMedica plc Press Release 06 November
- (2000)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.